This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

The next phase: Opportunities in China's pharmaceuticals market


DOWNLOAD  

As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second-largest LSHC market within this decade.

Organic market growth, driven by a combination of shifting age, wealth, and urbanisation demographics, is a second factor that has whetted the appetite of LSHC players. Many multinational players who have regarded China only as a source of raw materials or research are now contemplating China market entry. Others who have previously entered the market through joint ventures with Chinese companies and research institutes are now ready to ramp up their growth through drug licensing and acquisitions, where the right matches can be found. Key hurdles remain, among them discerning which targets have the desired capabilities, and which present unacceptable risks discoverable only through professional due diligence.

This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.

Share your comments

 

Stay connected